COMMUNIQUÉS West-GlobeNewswire

Amwell® to report third quarter 2026 operating results
26/10/2026
BOSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL a leading provider of technology-enabled care, will report third quarter 2026 operating results after stock market trading hours on Tuesday, November 3. [...]
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
26/10/2026
- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia - - SGT-212 is a first-in-class dual route FA [...]
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
26/10/2026
Seasoned public company CFO with deep autoimmune disease experience has helped raise more than $1 billion over a 20+ year biotech career Will lead the Company’s finance organization and capital strategy as it [...]
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
26/10/2026
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals Growing body of data supports ART26.12’s potential as a [...]
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
26/10/2026
- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer - -MAPKeeper 301 builds on [...]
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
26/10/2026
TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile [...]
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
26/10/2026
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
26/10/2026
COPENHAGEN, Denmark, October 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
26/10/2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS gains alongside [...]
NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026
26/10/2026
Company announcement no. 41 – 26 26 October 2026 NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026 Based on preliminary financial results for the third quarter of 2026, NTG expects adjusted [...]
Phathom Pharmaceuticals Provides Update on FDA Litigation
26/10/2026
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
TME Pharma extends financial visibility by lengthening debt maturity to June 2028
26/10/2026
TME Pharma extends financial visibility by lengthening debt maturity to June 2028 Financial visibility extended to second quarter of 2028 All existing debt holders, including the CEO and two members of the Supervisory [...]
TME Pharma améliore sa visibilité financière en prolongeant l'échéance de sa dette jusqu'en juin 2028
26/10/2026
TME Pharma améliore sa visibilité financière en prolongeant l'échéance de sa dette jusqu'en juin 2028 Visibilité financière prolongée jusqu'au deuxième trimestre 2028 Tous les détenteurs de dette existants, y compris le [...]
DXS International Plc (AQSE: DXSP): Notice of AGM
26/10/2026
26 October 2026 DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of AGM DXS International plc ( AQSE: DXSP ), the UK healthcare technology provider, announces that it has published its Notice of its Annual General Meeting (“ [...]
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
26/10/2026
Ad hoc announcement pursuant to Art. 53 LR In a Phase 2 study in pediatric insomnia disorder, in addition to marked improvements in sleep measures, daridorexant 50 mg showed an unexpected pattern of improvement in [...]
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
26/10/2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO ® — — ORPATHYS ® plus TAGRISSO ® [...]
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
25/10/2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
25/10/2026
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo [...]
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
25/10/2026
Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline NANJING, China, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nanjing [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum